News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,729 Results
Type
Article (39687)
Company Profile (247)
Press Release (658795)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204169)
Career Advice (2007)
Deals (35419)
Drug Delivery (95)
Drug Development (81044)
Employer Resources (172)
FDA (16181)
Job Trends (14857)
News (345189)
Policy (32537)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49434)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (124)
Approvals (16186)
Artificial intelligence (252)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (77)
Brain cancer (27)
Breast cancer (278)
Cancer (2250)
Cardiovascular disease (173)
Career advice (1676)
Career pathing (30)
CAR-T (150)
Cell therapy (421)
Cervical cancer (19)
Clinical research (65979)
Collaboration (832)
Compensation (524)
Complete response letters (19)
COVID-19 (2588)
CRISPR (40)
C-suite (240)
Cystic fibrosis (100)
Data (2195)
Decentralized trials (2)
Denatured (18)
Depression (42)
Diabetes (270)
Diagnostics (6367)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86602)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (112374)
Executive appointments (722)
FDA (17427)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (746)
Gene editing (104)
Generative AI (19)
Gene therapy (301)
GLP-1 (707)
Government (4415)
Grass and pollen (4)
Guidances (59)
Healthcare (18814)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16507)
IRA (40)
Job creations (3630)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (467)
Leadership (17)
Legal (7909)
Liver cancer (75)
Lung cancer (320)
Lymphoma (153)
Machine learning (7)
Management (58)
Manufacturing (303)
MASH (66)
Medical device (13375)
Medtech (13380)
Mergers & acquisitions (19455)
Metabolic disorders (682)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1910)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (39)
Obesity (362)
Opinion (204)
Ovarian cancer (75)
Pain (85)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (110)
Peanut (46)
People (57294)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20552)
Phase II (29054)
Phase III (21648)
Pipeline (1184)
Policy (138)
Postmarket research (2563)
Preclinical (8738)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5907)
Recruiting (65)
Regulatory (22271)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (68)
Series A (129)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3577)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (39)
The Weekly (29)
Vaccines (685)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (173)
Last 7 days (869)
Last 30 days (2624)
Last 365 days (32819)
2025 (10597)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37554)
2014 (31327)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27330)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (37834)
Australia (6184)
California (6100)
Canada (2008)
China (520)
Colorado (265)
Connecticut (272)
Delaware (146)
Europe (81251)
Florida (907)
Georgia (205)
Idaho (57)
Illinois (534)
India (25)
Indiana (306)
Iowa (11)
Japan (161)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (887)
Massachusetts (4550)
Michigan (219)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1719)
New Mexico (28)
New York (1737)
North Carolina (964)
North Dakota (8)
Northern California (2666)
Ohio (203)
Oklahoma (14)
Oregon (34)
Pennsylvania (1371)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (22)
South Dakota (1)
Southern California (2289)
Tennessee (101)
Texas (904)
United States (23016)
Utah (180)
Virginia (144)
Washington D.C. (61)
Washington State (550)
West Virginia (3)
Wisconsin (54)
698,729 Results for "agendia inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Agendia, Inc. Provides Review of Successful 2024
January 9, 2025
·
7 min read
Biotech Beach
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Agendia®, Inc., announced that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology Annual Meeting, taking place May 31st – June 4th, 2024, in Chicago, Illinois.
May 24, 2024
·
5 min read
Biotech Beach
Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO
Agendia ® , Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens.
May 31, 2024
·
5 min read
Biotech Beach
Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®
Agendia®, Inc., announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.
February 1, 2024
·
4 min read
Biotech Beach
Agendia Announces New Data Assessing the Immune Active State in HR+/HER2- Early-Stage Breast Cancer at 2024 ASCO
Agendia ® , Inc. today announced it will present new data characterizing the immune biology of MammaPrint High Risk tumors in an oral session at the 2024 Annual American Society of Clinical Oncology (ASCO) Meeting , taking place in Chicago, IL. on June 3rd, 2024.
May 31, 2024
·
5 min read
Press Releases
Agendia Announces Publication Validating MammaPrint® Utility in Prediction of Extended Endocrine Therapy Benefit
December 2, 2024
·
6 min read
Press Releases
Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024
November 26, 2024
·
4 min read
Press Releases
Agendia Demonstrates MammaPrint® Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
December 11, 2024
·
4 min read
Biotech Beach
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Agendia®, Inc. announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.
March 20, 2024
·
4 min read
Biotech Beach
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Agendia®, Inc., announced it will share new data from the ongoing prospective, observational FLEX Trial in two poster presentations at the 41st Annual Miami Breast Cancer Conference, taking place March 7 – 10th, 2024.
March 8, 2024
·
6 min read
1 of 69,873
Next
